The archive

137 stories from 60 issues. Filter by industry, type of news, date or company, and choose how much to read.

3 stories

Clear filters
  1. 21 OctNew

    Funding

    OpenAI buys Orchestra Bio to bring AI into drug development work

    Why it matters Biopharma teams now have OpenAI heading into their R&D operations, so reassess any AI workflow vendors you rely on.

    Impact Drug developers gain OpenAI-run AI for R&D operations, competing with existing workflow vendors.

    What happened OpenAI is buying Orchestra Bio, a company that applies AI to the day-to-day running of research and development in the life sciences. The aim is to help drug makers move treatments through development faster.

  2. 16 OctNew

    Programme

    OpenAI is giving university biology labs sponsored access to its science AI

    Why it matters Life sciences startups now compete for academic talent and partnerships with labs that get OpenAI's GPT-Rosalind through a sponsored plan.

    Impact Qualifying university biology labs get funded access to GPT-Rosalind and supporting tools.

    What happened OpenAI launched the Rosalind Academic Plan, which gives qualifying university research labs funded use of GPT-Rosalind plus supporting tools for life sciences work.

  3. 16 OctNew
    Google's AI platform helped scientists find a possible new antibiotic candidate, still untested in labs

    Why it matters Drug discovery teams can run a multi-database target search in one agent session, but the lead is only predicted, not lab-confirmed.

    Impact Agent platforms can scan protein databases for antibiotic leads, still awaiting lab validation.

    What happened Google DeepMind says biologists used its Antigravity agent platform to search millions of uncharacterized UniProt proteins with the ProtNLM model. They found one antimicrobial peptide candidate with predicted activity against respiratory pathogens, now in wet-lab validation.